Institute Quantivision

Institute Quantivision (iQ) - Bright with images

Mission Statement

The mission of Institute QuantiVision (iQ) is to develop medical imaging devices, software and protocols to enhance the efficiency, efficacy and economy of healthcare in the Netherlands, with focus on oncology and neurology. In particular, starting from clinical questions, iQ will develop high quality medical devices and protocols for quantitative analysis and integration of images at microscopic and macroscopic scale in order to improve diagnosis and therapy.
Healthcare improve­ment will be achieved by increasing diagnostic sensitivity, improving disease monitoring, improving localization of therapy, and improving evaluation of response to therapy.

To complete our mission, we aim to:

  • enable better, faster, and more affordable diagnosis and monitoring of patients.
  • improve therapeutic imaging support and enable image-guided optical biopsies that are more reliable, time-efficient, less invasive than standard tissue biopsies.
  • develop sophisticated data reduction and feature extraction methods, so that healthcare professionals can make optimal use of all available data without suffering from data overflow.
  • disseminate developed knowledge by education and devices and protocols in collaboration with industry, both nationally and internationally.

Aims and objectives

Starting from clinical questions, iQ will develop optical imaging devices, software and protocols to enhance efficiency, efficacy and economy of healthcare in the Netherlands, focusing on oncology and neurology. In particular, iQ aims at quantitative analysis and integration of images at a microscopic and macroscopic scale. Healthcare improvements will be made by enabling individualized and therefore optimized treatment. This will be achieved by quantitative analysis of multidimensional images, resulting in increased diagnostic sensitivity, improved monitoring of disease, improved monitoring of response to therapy and optimized therapy through image guided interventions. Devices, software and protocols developed within iQ will validated in clinical studies and will be disseminated both nationally and internationally in collaboration with industry.

Economic impact

IQ’s approach leads to increased efficiency in healthcare, improved diagnosis, new therapies, shorter treatment times for patients and practical solutions that will be adopted by industry and implemented in healthcare more quickly. Successful business developments and valorization are essential to iQ. As iQ focuses on translational research, clinically validated algorithms resulting from iQ will be of high healthcare and economical value. The work of the consortium will optimize quality and exchangeability of imaging equipment, which improves scientific accuracy and significance of findings obtained with this equipment. One of the main benefits of iQ will be that only those patients who will actually benefit will be selected for an (expensive) treatment, whilst non-responders can be offered alternative therapies without delay and without first suffering unnecessary toxicity as a result of ineffective therapy. Benefits will not only be experienced by healthcare professionals and their patients, but will also support the long-term (inter)national competitiveness of Dutch Industry and Science.


IQ aims to revolutionize the future of clinical practice, by enabling better, faster, and more affordable diagnosis and monitoring of patients. iQ developments will focus on clinical usefulness. As developments will be based on clinical needs, progress will be driven by a “clinical pull” rather than a “research push”, making sure that result of iQ are relevant for daily clinical practice. In ten years, iQ will have reached almost 75 milestones and deliveries in the area of image processing software, diagnostic and prognostic biomarkers, multi-purpose catheters, detection of neoplastic tissue, and (laser) microscopy.


Shining light on braintumors

Marloes Groot talks about her IMDI Quantivision Project in which she has developed a method to view in one minute instead of previously 16 hours, which (brain) cells are healthy and which contain tumor cells. “One of the projects I work on is developing a label free imaging technique that we’re goin … Lees meer

The Vasculuminator

The Vasculuminator is a clinical device to visualize blood vessels to increase the success of venipuncture and reduce complications during blood redrawing or intravenously administration of medication. The development of the vasculuminator is a good example of a problem or need for improved imaging … Lees meer

Image guidance in radiotherapy

Radiotherapy is an important treatment technique for cancer that 50% of cancer patients receive. Integrated image guidance (IGRT) systems have been recently introduced, enhancing the precision delivery to mm level in many situations. One of the most popular solutions is cone-beam CT integrated with … Lees meer

Technical leader:
Prof. Dr. T.G. van Leeuwen

The research of the Biomedical Photonics group of the Biomedical Engineering and Physics department of the AMC (headed by Ton van Leeuwen) focuses on the physics of the interaction of light with tissue, and to use that knowledge for the development, introduction and clinical evaluation of (newly developed) optical imaging and analysis techniques for gathering quantitative functional and molecular information of tissue or tissue sample ("optical biopsy"). The research bridges the gap between lab and clinic (“bench to bedside”).

Medical leader:
Prof. Dr. F. Barkhof

Frederik Barkhof received his MD from Vrije University, Amsterdam, The Netherlands in 1988 and defended his PhD thesis “Gadolinium-enhnaced MR imaging in multiple sclerosis”I n 1992, for which he received the Philips Prize for Radiology in 1992 and the Lucien Appel Prize for Neuroradiology in 1994. He currently serves as a full Professor in Neuroradiology at Vrije University Medical Centre (VUmc). As a neuroradiologist, he is a senior staff member of the MS Center Amsterdam, senior consultant of the Alzheimer Center and involved in the Centre for Childhood White Matter Disorders, Vumc, Amsterdam. He is the Scientific Director of the Image Analysis Centre (IAC), involved in analysis of multicentre drug trials. Prof. Barkhof is the chairman of the Ducth Society of Neuroradiology and the MAGNIMS study group. His serves on the Editorial boards of Brain, Eur Radiology, Neuroradiology, Journal of Neurology and JNNP.